Skip to main content

Advertisement

SpringerLink
Log in

Systemic Therapy Plus Thermal Ablation Versus Systemic Therapy Alone for Oligometastatic Liver Metastases from Non-small Cell Lung Cancer

  • Clinical Investigation
  • INTERVENTIONAL ONCOLOGY
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

Purpose

This study assessed and compared the efficacy and long-term outcomes of systemic therapy plus image-guided thermal ablation versus systemic therapy alone for oligometastatic liver metastases (LMs) from non-small cell lung cancer (NSCLC).

Materials and Methods

This retrospective study was approved by the institutional review board. Written informed consent was waived due to the retrospective design. From November 2012 to December 2017, 61 patients (mean age 59.0 years; 35 males) with oligometastatic LMs from NSCLC (≤ 5 metastatic lesions) who received systemic therapy with (n = 21, group A) or without (n = 40, group B) thermal ablation were analyzed. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan–Meier curves.

Results

The demographic and clinical characteristics were not significantly different between the groups (all P ≥ .05). In total, 28 LMs were entirely ablated, rendering a technical success rate of 100%, without major complications. The overall 6-month response rate was significantly higher in group A than in group B [57.1% (12/21) vs. 26.3% (10/38); P = .026]. The median PFS in group A was significantly longer than in group B [11.0 (95% CI 7.9–16.2) months vs. 5.2 (95% CI 3.7–7.9) months; P = .001]. However, the median OS was not significantly different [27.7 (95% CI 20.6–44.4) months vs. 17.7 (95% CI 14.5–27.5) months; P = .152].

Conclusion

Systemic therapy plus thermal ablation may prolong PFS but not OS in oligometastatic LMs from NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394.

    Article  Google Scholar 

  2. Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):27–39.

    Article  Google Scholar 

  3. Quint LE, Tummala S, Brisson LJ, et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg. 1996;62(1):246–50.

    Article  CAS  PubMed  Google Scholar 

  4. Funazo T, Nomizo T, Kim YH. Liver metastasis is associated with poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. J Thorac Oncol. 2017;12(9):e140–1.

    Article  PubMed  Google Scholar 

  5. Ren Y, Dai C, Zheng H, et al. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget. 2016;7(33):53245–53.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Wu KL, Tsai MJ, Yang CJ, et al. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung Cancer. 2015;88(2):187–94.

    Article  PubMed  Google Scholar 

  7. Riihimaki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78–84.

    Article  CAS  PubMed  Google Scholar 

  8. Hoang T, Dahlberg SE, Sandler AB, et al. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol. 2012;7(9):1361–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sridhar S, Paz-Ares L, Liu H, et al. Prognostic significance of liver metastasis in durvalumab-treated lung cancer patients. Clin Lung Cancer. 2019;20:e601.

    Article  CAS  PubMed  Google Scholar 

  10. Jiang T, Cheng R, Zhang G, et al. Characterization of liver metastasis and its effect on targeted therapy in EGFR-mutant NSCLC: a multicenter study. Clin Lung Cancer. 2017;18(6):631–639e2.

    Article  CAS  PubMed  Google Scholar 

  11. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–82.

    Article  CAS  PubMed  Google Scholar 

  12. Xu Q, Zhou F, Liu H, et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. J Thorac Oncol. 2018;13(9):1383–92.

    Article  PubMed  Google Scholar 

  13. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–8.

    Article  PubMed  Google Scholar 

  14. Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. McGhana JP, Dodd GD. Radiofrequency ablation of the liver: current status. AJR Am J Roentgenol. 2001;176(1):3–16.

    Article  CAS  PubMed  Google Scholar 

  16. Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57(4):794–802.

    Article  Google Scholar 

  17. Wang JH, Wang CC, Hung CH, et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 2012;56(2):412–8.

    Article  PubMed  Google Scholar 

  18. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology. 2008;47(1):82–9.

    Article  PubMed  Google Scholar 

  19. Sacks D, McClenny TE, Cardella JF, et al. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol. 2003;14(9 Pt 2):S199–202.

    Article  PubMed  Google Scholar 

  20. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

    Article  CAS  Google Scholar 

  21. Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501.

    Article  PubMed  Google Scholar 

  22. Tseng SE, Chiou YY, Lee YC, et al. Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases. Lung Cancer. 2014;86(2):225–30.

    Article  PubMed  Google Scholar 

  23. Jiang T, Chu Q, Wang H, et al. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases. Int J Cancer. 2019;144(10):2605–12.

    Article  CAS  PubMed  Google Scholar 

  24. Tsao MS, Sakurada A, Ding K, et al. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol. 2011;6(1):139–47.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was funded by National Key Research and Development Program of China (2017YFC0107800) and National Natural Science Foundation of China (81671798).

Author information

Authors and Affiliations

  1. Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan Nanli 17#, Chaoyang District, Beijing, 100021, China

    Yanqing Zhao, Xiaowu Zhang, He Zhao, Tao Gong, Jingui Li, Jiaywei Tsauo & Xiao Li

Authors
  1. Yanqing Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaowu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. He Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tao Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jingui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jiaywei Tsauo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jiaywei Tsauo or Xiao Li.

Ethics declarations

Conflict of interest

There is no conflict of interest to declare.

Ethical Approval

This retrospective study was approved by the Institutional Review Board of our institution.

Informed Consent

The need for informed consent was waived.

Consent for Publication

Consent for publication was obtained for all data included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, Y., Zhang, X., Zhao, H. et al. Systemic Therapy Plus Thermal Ablation Versus Systemic Therapy Alone for Oligometastatic Liver Metastases from Non-small Cell Lung Cancer. Cardiovasc Intervent Radiol 43, 1285–1293 (2020). https://doi.org/10.1007/s00270-020-02456-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-020-02456-y

Keywords

Search

Navigation